“The Truth Is, We Must Miss Some”: A Qualitative Study of the Patient Eligibility Screening Process, and Automation Perspectives, for Cancer Clinical Trials

Documenti analoghi

• Emergency cancer diagnosis in Paris: A cross‐sectional study using AP‐HP data
  di: Matthew E. Barclay, et al.
  Pubblicazione: (2025)
• Bridging Mammography and Lung Cancer Screening: Eligibility, Uptake and Potential Impact
  di: Ali Ajrouch, et al.
  Pubblicazione: (2026)
• Adherence to Breast Cancer Screening Guidelines Among Age‐Eligible US Women: Findings From NHIS 2021
  di: Monalisa Chandra, et al.
  Pubblicazione: (2025)
• Promoting Racial Justice in Cancer Clinical Trials: Community Engaged Solutions for Bridging Gaps
  di: Deana M. Williams, et al.
  Pubblicazione: (2025)
• Lenalidomide Plus Dexamethasone as FIRST‐Line Therapy in Transplant‐Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non‐Interventional Study FIRST ‐ NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial
  di: H. Nückel, et al.
  Pubblicazione: (2026)